BioArctic (OM:BIOA B) Rebounds Slightly, Is It Still Undervalued?

BioArctic (OM:BIOA B) drew fresh attention after its recent share move, with the stock gaining 1.7% in the latest session even as performance over the past month remained weaker.

The recent uptick comes after a tougher stretch, with the share price down 10.7% over the past month and 5% year to date, while longer term total shareholder returns of 2.1% over one year and 113.8% over five years suggest momentum has softened rather than broken.

Spot opportunities with a similar risk and reward profile by checking stocks in our hand picked 222 resilient stocks with low risk scores , which, like BioArctic, have been through recent share price swings.

Given BioArctic's recent pullback and a share price of SEK 295.4 against analyst estimates around SEK 314, the real focal point is simple: Does the current quote already reflect fair value or is the gap meaningful?

Most Popular Narrative: 7% Undervalued

On the numbers, the most followed narrative sees BioArctic's fair value at SEK 316.75, slightly above the latest SEK 295.4 close, so the current gap is modest rather than dramatic.

The market appears to be assigning high future growth expectations to BioArctic based on accelerating Leqembi (lecanemab) sales driven by an aging global population and the anticipated global rollout of more effective Alzheimer's diagnostics (such as FDA-approved blood-based biomarkers). Both of these factors are described as likely to support revenue growth in the next several years. Strong investor enthusiasm toward rapidly increasing healthcare expenditures and growing government/insurer willingness to fund high-value therapies are cited as supporting elevated valuation multiples, with expectations that BioArctic will retain pricing power and achieve continued margin expansion as Leqembi and pipeline assets scale globally.

See why 19 investors see BioArctic as 7% undervalued .

Result: Fair Value of SEK316.75 (UNDERVALUED)

Still, concentrated reliance on Leqembi, along with the ambitious shift in analyst assumptions on profit margins and revenue growth, could easily upset the current BioArctic valuation story.

Find out about the key risks to this BioArctic narrative .

Another View on BioArctic's Valuation

While analyst targets suggest BioArctic is modestly undervalued, the P/S ratio tells a tougher story. The stock trades on 26.1x sales compared with a fair ratio of 14.7x, the Swedish Biotechs average of 11.7x and peer levels around 7.1x, which points to valuation risk if expectations cool.

For investors weighing this richer pricing against the growth narrative, a central question is whether BioArctic's future execution can justify such a large premium before the market moves closer to that fair ratio.